Loading
Total declarations
Companies
▲ Purchases (17 ops.)
▼ Sales (0 ops.)
Latest filing published 29 Oct 2013 for SYNERGY PHARMACEUTICALS, INC., €36k.
Insider track record
Disclosed buys
17
Disclosed sells
0
Signal history
No signal scores available.
Closed purchases
Market purchases
17
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- +102.3%Entry US$255.60 · Close at T+365 US$516.96
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Gabriel Cerrone: trading record in brief
Gabriel Cerrone has filed trades across 4 companies (mainly through SEC (Form 4)), most often in Synergy Pharmaceuticals, Inc., Cardiff Oncology, Inc. and Inhibitex Inc. Over a trading history stretching from 19 September 2007 to 29 October 2013, the count stands at 26 filings.
Every open-market trade on record is a purchase: 17 purchases worth €1.4M, and no sale. The totals do not cover 2 filings with an undisclosed amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 6 share grants. 2013 to date brings 9 purchases and no sales.
Half of the purchases are above €27k and half below.
On 29 October 2013 came the latest disclosure, an open-market purchase for €36k in Synergy Pharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Gabriel Cerrone
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations26 total
12,000 shares@ US$4.09Common StockSEC:0001104659-13-078633:0
Canonical exit: 27 Jan 2014 (T+90)
8,000 shares@ US$4.42Common StockSEC:0001104659-13-049229:0
Canonical exit: 12 Sept 2013 (T+90)
12,500 shares@ US$4.46Common StockSEC:0001104659-13-032037:0
Canonical exit: 23 Jul 2013 (T+90)
5,500 shares@ US$4.66Common StockSEC:0001104659-13-032075:0
Canonical exit: 23 Jul 2013 (T+90)
1,000 shares@ US$6.04Common StockSEC:0001104659-13-007379:0
Canonical exit: 5 May 2013 (T+90)
4,000 shares@ US$6.18Common StockSEC:0001104659-13-007379:1
Canonical exit: 6 May 2013 (T+90)
13,090 shares@ US$6.04Common StockSEC:0001104659-13-007045:0
Canonical exit: 5 May 2013 (T+90)
6,000 shares@ US$5.97Common StockSEC:0001104659-13-006700:0
Canonical exit: 30 Apr 2013 (T+90)
20,000 shares@ US$5.99Common StockSEC:0001104659-13-006700:1
Canonical exit: 30 Apr 2013 (T+90)
6,000 shares@ US$5.97Common StockSEC:0001104659-13-005887:0
20,000 shares@ US$5.99Common StockSEC:0001104659-13-005887:1
393,023 sharesCommon StockSEC:0001104659-13-003874:0
2,184,672 sharesCommon StockSEC:0001104659-13-003842:0
393,023 sharesCommon StockSEC:0001104659-13-003959:0
40,000 shares0Common StockSEC:0001104659-12-084986:0
Canonical exit: 10 Mar 2013 (T+90)
87,820 shares@ US$3.61Common StockSEC:0001104659-12-078129:0
Canonical exit: 12 Feb 2013 (T+90)
300 shares@ US$2.15Common StockSEC:0001104659-12-058850:0
Canonical exit: 15 Nov 2012 (T+90)
7,500 shares@ US$2.36Common StockSEC:0001104659-12-058850:1
Canonical exit: 18 Nov 2012 (T+90)
15,000 shares@ US$2.24Common StockSEC:0001104659-12-058599:0
Canonical exit: 14 Nov 2012 (T+90)
200,000 shares@ US$0.50Common StockSEC:0001104659-12-025725:0
Canonical exit: 12 Jul 2012 (T+90)
470,588 shares@ US$2.13Common StockSEC:0001104659-11-064130:0
Canonical exit: 12 Feb 2012 (T+90)
12,935 sharesCommon StockSEC:0001104659-10-058934:0
Canonical exit: 13 Feb 2011 (T+90)
435,600 shares0Common StockSEC:0000894579-08-000084:0
435,600 shares0Common StockSEC:0000894579-08-000084:1
1,666,500 sharesCommon stockSEC:0001209191-07-054569:1
25 of 26 declarations
